NASOPHARYNGEAL CARCINOMA

This study tests whether giving three drugs (gemcitabine, docetaxel, and toripalimab) before standard radiation can safely improve outcomes for people with a specific throat cancer caused by the Epstein-Barr virus. About 24 adults with advanced but not spread cancer will receive …

This study looks at whether people with a type of throat cancer linked to the Epstein-Barr virus can safely receive lower doses of radiation after initial chemotherapy. The goal is to see if reducing radiation can still control the cancer while causing fewer long-term side effect…

This early-stage trial tests a radioactive drug that seeks out and delivers radiation directly to cancer cells with a specific protein (somatostatin receptor). It is for adults with advanced lung, kidney, head and neck, digestive tract, or adrenal gland tumors that cannot be remo…

This early-phase trial is testing a new approach for people with head and neck cancer that has returned or spread after standard chemotherapy. The treatment combines a gene therapy injection (EDS01) given directly into a tumor with an immunotherapy drug (toripalimab) given throug…

This phase 3 trial tests whether adding toripalimab (an immunotherapy) to capecitabine (a chemotherapy pill) as maintenance therapy works better than capecitabine alone for people with high-risk nasopharyngeal carcinoma. The study enrolls 264 adults aged 18-70 who have completed …

This study tests a new drug called Becotatug Vedotin in children aged 2 to 18 with certain solid tumors that have come back or spread. The drug targets a protein called EGFR found on many cancer cells. The main goal is to see if the drug is safe and to find the best dose, while a…

This phase 3 trial tests whether a structured nutrition plan (including supplements, feeding tubes, or IV nutrition) helps malnourished patients with advanced nasopharyngeal carcinoma maintain weight and improve their prognosis. About 266 participants will receive either standard…

This phase II trial is testing whether combining two types of radiation (SBRT and low-dose radiation) with an immunotherapy drug (toripalimab) and chemotherapy can help control recurrent or metastatic nasopharyngeal carcinoma. The study will enroll 148 participants who have not r…

This phase 3 trial tests whether adding an immunotherapy drug (cadonilimab) and low-dose radiation to standard chemotherapy can improve outcomes for people with advanced nasopharyngeal cancer. About 380 participants will be randomly assigned to receive either the new combination …

This phase 3 trial tests whether adding an immunotherapy drug called toripalimab to standard chemoradiotherapy helps people with recurrent nasopharyngeal carcinoma live longer. About 212 participants whose cancer has returned after prior treatment and who cannot have surgery will…

This study tests a new drug called BL-B01D1 combined with an immunotherapy (PD-1 antibody) in people with advanced lung cancer, nasopharyngeal cancer, or other solid tumors that have spread. The goal is to see if the combination can shrink tumors and control the disease. About 57…

This phase 3 trial tests whether adding a precise form of radiation (SBRT) to the immunotherapy drug camrelizumab helps control cancer better than camrelizumab alone in people with nasopharyngeal cancer that has spread to a few spots (oligometastatic). About 188 adults whose prim…

This phase 2 trial is testing whether a year-long combination of tislelizumab (an immunotherapy) and low-dose capecitabine (a chemotherapy pill) can prevent cancer relapse in 53 patients with high-risk nasopharyngeal carcinoma. Participants have already received standard chemothe…

This early-phase study tests whether specially engineered immune cells (CAR-T and TCR-T) can safely fight Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma that has returned or not responded to treatment. About 24 adults will receive one of two types of cell therapy, wit…

This phase 3 trial is testing whether a lower dose of radiation, combined with chemotherapy and an immunotherapy drug called Camrelizumab, can control stage III nasopharyngeal cancer as well as the standard higher dose. About 593 patients whose tumors respond well to initial trea…

This phase II trial is testing whether adding an immunotherapy drug (envafolimab) and a blood-vessel blocker (endostatin) to standard chemoradiotherapy can improve outcomes for 30 people with locally advanced nasopharyngeal carcinoma. The main goal is to see how many patients hav…

This study compares a lower dose of radiation (40.2Gy) to the standard dose (49.2Gy) for people with stage II nasopharyngeal cancer that responds well to chemotherapy. All participants also receive immunotherapy. The goal is to see if the lower dose can control the cancer just as…

This phase II trial tests two drugs, SI-B003 and BL-B01D1, alone or together in 121 adults with advanced non-small cell lung cancer or nasopharyngeal carcinoma. The goal is to see if the combination shrinks tumors and to find the safest, most effective dose. Participants must hav…

This phase 2 trial tests whether adding two immunotherapy drugs (pembrolizumab and bevacizumab) to standard chemotherapy (gemcitabine and cisplatin) works better for advanced nasopharyngeal cancer. About 50 participants will be randomly assigned to receive either the standard che…

This study tests whether giving radiation only to specific neck areas based on where cancer has spread can reduce side effects and improve quality of life for people with nasopharyngeal cancer. About 470 newly diagnosed patients will receive either standard or personalized neck r…

This study tests a special PET/CT scan that uses radioactive tracers to find cancers that have a protein called CD70 on their surface. The cancers being studied include kidney cancer, lymphoma, and nasopharyngeal cancer. About 300 adults will receive an injection of the tracer an…

This early-stage study is testing a new imaging agent called 68Ga-FL-031 to see if it can better detect and stage certain cancers, including small cell lung, breast, and nasopharyngeal tumors. Ten adults with suspected or confirmed cancer will receive both the new PET scan and a …

This early-stage trial tests a cream made from inactivated Akkermansia muciniphila bacteria to prevent skin injury in 40 breast or head/neck cancer patients receiving radiation. The cream is applied three times daily to the radiation area. The main goal is to see if it is safe an…

This study tests whether a chlorhexidine spray can prevent severe skin reactions caused by radiation therapy in people with nasopharyngeal cancer. About 148 participants will use the spray or a placebo during their treatment. The goal is to see if the spray reduces the chance of …

This study tests a new cream made from amino acids to prevent skin damage caused by radiation therapy in people with head and neck cancer. About 40 participants will use the cream during their radiation treatment. The goal is to see if it reduces skin redness, pain, and treatment…

This study tests a liquid made from cockroach extract (Meilian Fuxin) to prevent severe skin damage in head and neck cancer patients receiving radiation therapy. About 60 participants will apply the solution to their skin during treatment. The goal is to see if it reduces the ris…

This phase 3 trial tests whether Houyanqing Oral Liquid, a Chinese herbal mix, can prevent or reduce severe mouth sores caused by radiation therapy in 386 nasopharyngeal cancer patients. Participants take the liquid four times daily during radiation, alongside standard care. The …

This study looks at 50 people with nasopharyngeal cancer that has come back or spread. Researchers will use advanced lab tests (multi-omics) to see if they can predict how well a combination of chemotherapy, radiation, and immunotherapy works. The goal is to find better ways to p…

This international study aims to improve how doctors stage nasopharyngeal cancer by collecting data from 5,000 patients across multiple countries. Researchers will use this information to refine the TNM staging system and combine it with other factors like biomarkers. The goal is…

This large observational registry aims to collect data from over 13,000 adults across Europe with rare head and neck cancers, including cancers of the nasopharynx, nasal cavity, salivary glands, and middle ear. Researchers will track patient outcomes like survival, treatment resp…

This study enrolls 500 adults with nasopharyngeal carcinoma (stage I-III) who are receiving chemoradiotherapy with either proton or photon radiation. Researchers will collect imaging scans and blood samples to find markers that predict how well the cancer responds, side effects, …